The company's growth was largely driven by its drug Dupixent, which saw sales climb 30.8% year-over-year. Revenue was further supported by new drugs, including Altuviiio and Ayvakit. On a regional basis, Sanofi experienced exceptional growth in the United States, with sales increasing by 26.2%. The analyst rating adjustment also coincides with a leadership transition. As highlighted by GlobeNewswire, Belén Garijo was appointed Chief Executive Officer on May 1, 2026. The Board of Directors noted her appointm ...